首页> 外文期刊>Frontiers in Endocrinology >Thyroid-Stimulating Hormone Receptor Antibodies in Pregnancy: Clinical Relevance
【24h】

Thyroid-Stimulating Hormone Receptor Antibodies in Pregnancy: Clinical Relevance

机译:妊娠中促甲状腺激素受体抗体的临床意义

获取原文
           

摘要

Graves’ disease is the most common cause of thyrotoxicosis in women of childbearing age. Approximately 1% of pregnant women been treated before, or are being treated during pregnancy for Graves’ hyperthyroidism. In pregnancy, as in not pregnant state, thyroid-stimulating hormone (TSH) receptor (TSHR) antibodies (TRAbs) are the pathogenetic hallmark of Graves’ disease. TRAbs are heterogeneous for molecular and functional properties and are subdivided into activating (TSAbs), blocking (TBAbs), or neutral (N-TRAbs) depending on their effect on TSHR. The typical clinical features of Graves’ disease (goiter, hyperthyroidism, ophthalmopathy, dermopathy) occur when TSAbs predominate. Graves’ disease shows some peculiarities in pregnancy. The TRAbs disturb the maternal as well as the fetal thyroid function given their ability to cross the placental barrier. The pregnancy-related immunosuppression reduces the levels of TRAbs in most cases although they persist in women with active disease as well as in women who received definitive therapy (radioiodine or surgery) before pregnancy. Changes of functional properties from stimulating to blocking the TSHR could occur during gestation. Drug therapy is the treatment of choice for hyperthyroidism during gestation. Antithyroid drugs also cross the placenta and therefore decrease both the maternal and the fetal thyroid hormone production. The management of Graves’ disease in pregnancy should be aimed at maintaining euthyroidism in the mother as well as in the fetus. Maternal and fetal thyroid dysfunction (hyperthyroidism as well as hypothyroidism) are in fact associated with several morbidities. Monitoring of the maternal thyroid function, TRAbs measurement, and fetal surveillance are the mainstay for the management of Graves’ disease in pregnancy. This review summarizes the biochemical, immunological, and therapeutic aspects of Graves’ disease in pregnancy focusing on the role of the TRAbs in maternal and fetal function.
机译:格雷夫斯病是育龄妇女甲状腺毒症的最常见原因。大约有1%的孕妇因Graves甲状腺功能亢进症在怀孕之前或在怀孕期间接受过治疗。在怀孕期间,与未怀孕状态一样,甲状腺刺激激素(TSH)受体(TSHR)抗体(TRAbs)是Graves病的致病性标志。 TRAb具有不同的分子和功能特性,根据其对TSHR的影响,可分为激活(TSAb),阻断(TBAb)或中性(N-TRAb)。当TSAb占主导地位时,就会出现Graves病的典型临床特征(甲状腺肿,甲状腺功能亢进,眼病,皮肤病)。格雷夫斯病在怀孕期间表现出一些特殊性。 TRAbs能够穿过胎盘屏障,因此会干扰孕妇和胎儿的甲状腺功能。在大多数情况下,与怀孕相关的免疫抑制可降低TRAb的水平,尽管它们在患有活动性疾病的妇女以及在妊娠前接受过明确治疗(放射性碘或手术)的妇女中仍然存在。在妊娠期间可能会发生功能特性从刺激到阻断TSHR的变化。药物治疗是妊娠期甲亢的首选治疗方法。抗甲状腺药物也可穿过胎盘,因此会降低孕妇和胎儿甲状腺激素的产生。妊娠期间格雷夫斯病的治疗应旨在维持母亲和胎儿的甲状腺功能正常。孕妇和胎儿的甲状腺功能障碍(甲状腺功能亢进症和甲状腺功能减退症)实际上与多种疾病有关。监测孕妇甲状腺功能,TRAbs测量和胎儿监护是妊娠Graves病管理的主要手段。这篇综述总结了妊娠期间格雷夫斯病的生化,免疫学和治疗学方面,重点是TRAbs在母体和胎儿功能中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号